Chronic Inflammatory Demyelinating Polyneuropathy

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a neurological disorder characterized by progressive weakness and impaired sensory function in the arms and legs.

Featured Video

European Academy of Neurology (EAN) and Peripheral Nerve Society (PNS) Guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force—Second Revision

CIDP

Watch Dr. Peter Van den Bergh, lead author, take you through the highlights of the guideline.

Videos about CIDP

VIEW ALL VIDEOS

Incidence of GBS and CIDP Following Influenza Vaccination

Peter Donofrio, MD

Vanderbilt University Medical Center, Nashville, TN, USA

25:18 MIN

CIDP
GBS

Gain an understanding of the existing surveillance data, studies and facts associated with the influenza vaccine as it relates to GBS and CIDP.

DOWNLOAD PDF

The GRIPPER study: Quantifying IVIG Treatment-Related Fluctuations in CIDP Using Daily Grip Strength Measurements

Jeffrey A. Allen, MD

University of Minnesota

12:15 MIN

CIDP

Learn more about grip strength as an outcome measure in CIDP and how it is utilized in the Gripper Study as a daily measure of treatment-related fluctuations in IVIg-treated patients.

DOWNLOAD PDF

Consistency Over Time of Strength and Disability Measurements in Patients with CIDP on Stable IgG Therapy

Mel Berger, MD, PhD

Medical Research Strategy, CSL Behring

8:25 MIN

CIDP

Hear the results of a study to understand wear-off effects in CIDP patients during IVIg therapy.

DOWNLOAD PDF

Dosing Schedules for IVIg: The Use of an Algorithm as a Suggestion for Personalized Dosing

Michael Lunn, PhD

National Hospital for Neurology and Neurosurgery, Queen Square, London

14:01 MIN

CIDP

Learn how an algorithm could be used to personalize dosing schedules for IVIg.

DOWNLOAD PDF

NOW PLAYING

25:18

Incidence of GBS and CIDP Following Influenza Vaccination

Gain an understanding of the existing surveillance data, studies and facts associated with the influenza vaccine as it relates to GBS and CIDP.

NOW PLAYING

12:15

The GRIPPER study: Quantifying IVIG Treatment-Related Fluctuations in CIDP Using Daily Grip Strength...

Learn more about grip strength as an outcome measure in CIDP and how it is utilized in the Gripper Study as a daily measure of treatment-related fluctuations in IVIg-treated patients.

NOW PLAYING

8:25

Consistency Over Time of Strength and Disability Measurements in Patients with CIDP on Stable IgG Th...

Hear the results of a study to understand wear-off effects in CIDP patients during IVIg therapy.

NOW PLAYING

14:01

Dosing Schedules for IVIg: The Use of an Algorithm as a Suggestion for Personalized Dosing

Learn how an algorithm could be used to personalize dosing schedules for IVIg.

Our Experts on CIDP

VIEW ALL EXPERTS

Jeffrey A. Allen, MD

University of Minnesota

Jeffrey A. Allen, MD

University of Minnesota

CIDP
MMN

Dr. Jeffrey Allen is a neuromuscular specialist and clinical investigator at the University of Minnesota in Minneapolis.

Karissa Gable, MD

Duke University Medical Center in Durham, North Carolina

Karissa Gable, MD

Duke University Medical Center in Durham, North Carolina

CIDP

Dr. Karissa Gable is a Neuromuscular specialist at Duke University Medical Center in Durham, North Carolina.

Carol L. Koski, MD

GBS/CIDP Foundation International

Carol L. Koski, MD

GBS/CIDP Foundation International

CIDP
GBS

Dr. Koski is a retired Professor of Neurology from the University of Maryland School of Medicine and is currently a Director of the GBS/CIDP Foundation International.

Michael Lunn, PhD

National Hospital for Neurology and Neurosurgery, Queen Square, London

Michael Lunn, PhD

National Hospital for Neurology and Neurosurgery, Queen Square, London

CIDP

Dr Michael Lunn is a Consultant Neurologist, Clinical Lead in Neuroimmunology and Honorary Senior Lecturer at the National Hospital for Neurology and Neurosurgery.

What is Chronic Inflammatory
Demyelinating Polyneuropathy (CIDP)?

What are the symptoms of CIDP?

How is CIDP treated?